We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
-8.25%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$3.75B
AUM Growth
-$833M
Cap. Flow
-$27.3M
Cap. Flow %
-0.73%
Top 10 Hldgs %
47.18%
Holding
110
New
14
Increased
9
Reduced
11
Closed
22

Top Buys

Rank Stock Value
1
VERU icon
Veru
VERU
+$91.7M
2
PEPG icon
PepGen
PEPG
+$90.7M
3
NSTG
NanoString Technologies, Inc.
NSTG
+$66.8M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$36.2M
5
NKTX icon
Nkarta
NKTX
+$28.9M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$60.4M
2
MGNX icon
MacroGenics
MGNX
+$53.8M
3
NVAX icon
Novavax
NVAX
+$51M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$32.1M
5
CCXI
ChemoCentryx, Inc.
CCXI
+$29M

Sector Composition

Rank Sector Weight
1 Healthcare 98.19%
2 Financials 1.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HOWL icon
51
Werewolf Therapeutics
HOWL
$17.2M
$17.6M 0.47%
4,291,881
– –
DALS
52
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
$14.5M 0.39%
1,500,000
– –
CNCE
53
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$13.9M 0.37%
3,307,203
+273,600
+9% +$1.08M
MIST icon
54
Milestone Pharmaceuticals
MIST
$138M
$13.8M 0.37%
2,246,503
– –
ACHL
55
DELISTED
Achilles Therapeutics
ACHL
$12.6M 0.34%
5,014,687
– –
BLSA
56
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$12.4M 0.33%
1,250,000
– –
OTIC
57
DELISTED
Otonomy, Inc.
OTIC
$11.6M 0.31%
5,600,000
– –
LIAN
58
DELISTED
LianBio American Depositary Shares
LIAN
$9.98M 0.27%
4,622,574
-3,032,441
-40% -$10.3M
FLACU
59
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
$9.87M 0.26%
1,000,000
– –
ARYE
60
DELISTED
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
$9.72M 0.26%
1,000,000
– –
RLAY icon
61
Relay Therapeutics
RLAY
$4.1B
$9.2M 0.25%
549,055
– –
IOBT
62
DELISTED
IO Biotech
IOBT
$8.68M 0.23%
1,857,755
– –
SLDB icon
63
Solid Biosciences
SLDB
$794M
$7.61M 0.2%
824,525
– –
FVAM
64
DELISTED
5:01 Acquisition Corp
FVAM
$7.42M 0.2%
750,000
– –
SYBX
65
DELISTED
Synlogic
SYBX
$6.7M 0.18%
388,391
-56,053
-13% -$1.21M
BDTX icon
66
Black Diamond Therapeutics
BDTX
$96.8M
$6.37M 0.17%
2,589,904
– –
IPSC icon
67
Century Therapeutics
IPSC
$364M
$6.36M 0.17%
756,821
-157,273
-17% -$1.54M
OBIO icon
68
Orchestra BioMed
OBIO
$238M
$6.22M 0.17%
625,000
– –
CNTB
69
Connect Biopharma Holdings
CNTB
$127M
$6.08M 0.16%
6,991,003
– –
BMEA icon
70
Biomea Fusion
BMEA
$84.6M
$5.99M 0.16%
500,000
– –
LONA
71
LeonaBio Inc
LONA
$66.3M
$5.73M 0.15%
+187,800
New +$17.2M
XLO icon
72
Xilio Therapeutics
XLO
$59.9M
$4.82M 0.13%
117,837
-25,179
-18% -$1.33M
WHWK
73
Whitehawk Therapeutics
WHWK
$190M
$4.72M 0.13%
+383,028
New +$5.69M
LAB icon
74
Standard BioTools
LAB
$340M
$3.18M 0.08%
+1,987,589
New +$4.92M
ENTX icon
75
Entera Bio
ENTX
$147M
$3.13M 0.08%
2,353,000
– –
1 2
3
4 5

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q2 2022 Portfolio in Review

As of Q2 2022, RA Capital Management held 110 positions worth $3.75B, down 18% from $4.58B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

RA Capital Management's Q2 2022 filing shows 14 new, 9 increased, 11 reduced and 22 closed positions. Its largest new stake was Veru: 790,000 shares worth $89.3M. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $60.4M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials.

  • RA Capital Management's largest Q2 2022 buy was Veru: 790,000 shares worth $89.3M.
  • RA Capital Management added most to Aclaris Therapeutics in Q2 2022, an estimated $36.2M increase.
  • RA Capital Management's biggest Q2 2022 reduction was LianBio American Depositary Shares, cutting an estimated $10.3M.
  • RA Capital Management fully exited Mirati Therapeutics, Inc. Common Stock in Q2 2022, selling an estimated $60.4M.
  • RA Capital Management's ten largest holdings make up 47% of its $3.75B portfolio in Q2 2022.
  • RA Capital Management opened 14 new positions and closed 22 in Q2 2022.
  • RA Capital Management's portfolio value fell 18% quarter-over-quarter to $3.75B.

Based on RA Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.